In-Vitro Toxicology Testing Market Size, Share, Opportunities, And Trends By Product (Assays, Software, Consumables, Services, Instruments), By Technology (OMICS Technology, Cell Culture Technology, High Throughput Technology, Molecular Imaging Technology), By Method (In Silico, Biochemical Assay, Cellular Assay, Ex-vivo), By Application (Endocrine Disruption, Dermal Toxicity, Systemic Toxicology, Ocular Toxicity, Others), By End-user (Cosmetics & Household Products, Pharmaceutical Industry, Diagnostics, Academic Institutes & Research Laboratories, Food Industry, Chemicals Industry, Others), And By Geography - Forecasts From 2024 To 2029

The In-vitro toxicology testing market is anticipated to expand at a high CAGR over the forecast period.

The market for in-vitro toxicology testing is expanding significantly due to several causes. The need for in-vitro testing techniques that provide accurate toxicity assessment while reducing ethical issues and maximizing cost-effectiveness is rising as regulatory bodies push more and more for alternatives to conventional animal testing. Using grown cells, tissues, or organoids, in-vitro toxicity testing evaluates the possible negative effects of chemicals on biological systems. These techniques offer insightful information about the safety profile of chemicals, cosmetics, medicines, and other consumer goods, which helps with risk assessment and decision-making for product development and regulatory approval.

Furthermore, developments in computer models, high-throughput screening methods, and cell culture technologies support and enhance the use of in-vitro toxicity testing. The market for in-vitro toxicology testing is expected to grow due to the growing emphasis on human-relevant testing methods and growing awareness of the drawbacks of using animal models. This presents exciting prospects for new product development and market expansion in the fields of toxicology research and regulatory compliance.

Market Drivers:

• Regulatory compliance is anticipated to boost the In-vitro toxicology testing market.

One major factor propelling the market expansion for in-vitro toxicology testing is regulatory concerns. Global standards are becoming more and more strict, requiring the evaluation of chemical safety and toxicity before product release. Because of ethical concerns and technological developments, regulatory authorities are emphasizing the use of alternative testing methods, like in-vitro techniques, to replace or minimize reliance on animal testing.

Regulatory agencies also acknowledge that conventional animal models have limitations when it comes to correctly forecasting toxicity to humans. As a result, there is an increasing need for in-vitro diagnostics that offer more accurate and pertinent information about the hazards to human health. Because of the need to abide by these rules, businesses in sectors including pharmaceuticals, chemicals, food and beverage, and cosmetics have used in-vitro toxicology testing techniques to guarantee product safety, regulatory compliance, and public health protection.

The current regulatory framework fosters an atmosphere conducive to the in-vitro toxicity testing industry expansion. In January 2022, Natera, Inc., the leading provider of individualized genetic testing and diagnostics, entered the early cancer detection (ECD) sector to support the company's strategic growth goals in the rapidly developing fields of screening and ECD.

• Technological advancements are expected to boost the In-vitro toxicology testing market.

The in-vitro toxicity testing industry is expanding thanks in large part to technological improvements. The predictive value of in-vitro assays is increased by advances in cell culture techniques, such as organ-on-a-chip models and three-dimensional (3D) cell cultures, which allow for a more realistic simulation of human physiology and organ systems. Testing procedures are streamlined by automation and robots, which lowers labor costs and increases throughput and reproducibility. Comprehensive investigation of cellular responses to toxicants is made possible by high-content screening platforms and imaging technologies, which support data-driven decision-making in toxicity assessment.

Additionally, the integration of various information and the creation of predictive toxicological models are made possible by developments in computational modeling, artificial intelligence, and machine learning, which improve the effectiveness and precision of toxicity predictions. All things considered, these technological developments improve the in-vitro toxicity testing methods' dependability, effectiveness, and affordability, which propels their use across sectors and helps the market growth.

In January 2023, to create a fully functional, cutting-edge laboratory campus in Genome Valley, Hyderabad, Eurofins Scientific, a global leader in the scientific field of bioanalytical testing as well as food, environment, pharmaceutical, and cosmetic product testing, announced the acquisition of assets. A facility that can support small biotech businesses and large pharmaceutical companies worldwide in the fields of synthetic organic chemistry, analytical R&D, bioanalytical services (for large and small molecules), in-vivo pharmacology, safety toxicology, and formulation R&D is part of the acquisition. The modern laboratories take up more than 90,000 square feet.

• Advancements in In-vitro diagnostics are anticipated to boost the In-vitro toxicology testing market.

The field of in vitro toxicity testing has experienced substantial growth as a result of the market expansion for in vitro diagnostics. There is a growing need for safer and more effective ways to evaluate the possible toxicity of drugs, chemicals, and consumer goods, as improvements in diagnostic technologies allow for the more accurate and sensitive identification of biomarkers and biochemical alterations suggestive of toxicity. The market is growing because in vitro toxicity testing uses these diagnostic methods to assess and forecast negative effects on living systems without using animals. This mutually beneficial relationship between toxicological testing and diagnostic innovation highlights how crucial technology advancements are to the advancement of safety assessments in all sectors of the economy.

According to Medtech Europe, In vitro diagnostics, or IVDs, are a vital component of modern medicine. Up to 70% of clinical choices are influenced by the results of in vitro testing, while IVDs only make up 1% of healthcare spending in the EU-27, the UK, and EFTA. Since 2013, the IVD market has been stagnant with slight growth. In 2020, however, due to the COVID-19 pandemic and the high demands for SARS-Cov-2 testing, the IVD market has experienced an increase of + 25,4%. In 2021, we witness an unprecedented record growth of 41.2%

Asia Pacific region is expected to grow significantly.

The market for in-vitro toxicity testing is expanding significantly in the Asia Pacific area. Several causes, including growing industrialization, fast urbanization, and strict regulatory frameworks encouraging the use of alternative testing methods, are driving this expansion. Furthermore, the need for in-vitro toxicity testing is driven by growing investments in healthcare infrastructure, the growth of the pharmaceutical and biotechnology industries, and an increasing emphasis on animal welfare.

Additionally, because of their developing research capacities and increased focus on product safety and regulatory compliance, the region's developing economies—such as China and India—offer market participants lucrative potential. These elements work together to support the Asia Pacific region's strong in-vitro toxicology testing market growth.

 Market Restraints:

• Accuracy and relevance to human responses can constrain the market for In-vitro toxicology testing.

A significant obstacle facing the in vitro toxicity testing industry is attaining adequate prediction precision and pertinence to human reactions. Even while there are benefits to using in vitro techniques, like cost-effectiveness and ethical considerations, it is still challenging to correctly replicate intricate physiological processes and intercellular connections. Enhancing the in vitro-in vivo correlation is critical to increasing the acceptability and reliability of these testing methodologies, particularly in regulatory decision-making processes that guarantee human safety.

Market Development:

• May 2023- The UK-based worldwide immunodiagnostics developer Oncimmune Ltd., with a commercialized CE-IVD, marked EarlyCDT Lung blood test, autoantibody platform, and research and development pipeline of seven+ cancer detection signatures, bought by privately held biotech business Freenome. It is used to identify individuals with lung cancer who have early stages of the disease by looking for high levels of autoantibodies produced by their immune systems.
• March 2023- The groundbreaking electron capture dissociation (ECD) technology known as the ExD cell was developed by e-MSion, an early-stage firm that Agilent Technologies Inc. announced it was acquiring. Using the ExD cell, a portable mass spectrometer, biologists can create biotherapeutic drugs to cure illnesses faster.

Market Segmentation:

• By  Product
  • Assays
  • Software
  • Consumables
  • Services
  • Instruments
• By Technology
  • OMICS Technology
  • Cell Culture Technology
  • High Throughput Technology
  • Molecular Imaging Technology
• By Method
  • In Silico
  • Biochemical Assay
  • Cellular Assay
  • Ex-vivo
• By Application
  • Endocrine Disruption
  • Dermal Toxicity
  • Systemic Toxicology
  • Ocular Toxicity
  • Others
• By End-user
  • Cosmetics & Household Products
  • Pharmaceutical Industry
  • Diagnostics
  • Academic Institutes & Research Laboratories
  • Food Industry
  • Chemicals Industry
  • Others
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • South America
    • Brazil
    • Argentina
    • Others
  • Europe
    • United Kingdom
    • Germany
    • France
    • Italy
    • Spain
    • Others
  • Middle East and Africa
    • Saudi Arabia
    • UAE
    • Others
  • Asia Pacific
    • Japan
    • China
    • India
    • South Korea
    • Taiwan
    • Thailand
    • Indonesia
    • Others

1. INTRODUCTION

1.1. Market Overview

1.2. Market Definition

1.3. Scope of the Study

1.4. Market Segmentation

1.5. Currency

1.6. Assumptions

1.7. Base and Forecast Years Timeline

1.8. Key Benefits for the Stakeholder

2. RESEARCH METHODOLOGY  

2.1. Research Design

2.2. Research Processes

3. EXECUTIVE SUMMARY

3.1. Key Findings

3.2. Analyst View

4. MARKET DYNAMICS

4.1. Market Drivers

4.2. Market Restraints

4.3. Porter’s Five Forces Analysis

4.3.1. Bargaining Power of Suppliers

4.3.2. Bargaining Power of Buyers

4.3.3. Threat of New Entrants

4.3.4. Threat of Substitutes

4.3.5. Competitive Rivalry in the Industry

4.4. Industry Value Chain Analysis

4.5. Analyst View

5. IN-VITRO TOXICOLOGY TESTING MARKET BY PRODUCT 

5.1. Introduction

5.2. Assays

5.2.1. Market Trends and Opportunities

5.2.2. Growth Prospects

5.3. Software

5.3.1. Market Trends and Opportunities

5.3.2. Growth Prospects

5.4. Consumables

5.4.1. Market Trends and Opportunities

5.4.2. Growth Prospects

5.5. Services

5.5.1. Market Trends and Opportunities

5.5.2. Growth Prospects

5.6. Instruments

5.6.1. Market Trends and Opportunities

5.6.2. Growth Prospects

6. IN-VITRO TOXICOLOGY TESTING MARKET BY TECHNOLOGY

6.1. Introduction

6.2. OMICS Technology

6.2.1. Market Trends and Opportunities

6.2.2. Growth Prospects

6.3. Cell Culture Technology

6.3.1. Market Trends and Opportunities

6.3.2. Growth Prospects

6.4. High Throughput Technology

6.4.1. Market Trends and Opportunities

6.4.2. Growth Prospects

6.5. Molecular Imaging Technology

6.5.1. Market Trends and Opportunities

6.5.2. Growth Prospects

7. IN-VITRO TOXICOLOGY TESTING MARKET BY METHOD 

7.1. Introduction

7.2. In Silico

7.2.1. Market Trends and Opportunities

7.2.2. Growth Prospects

7.3. Biochemical Assay

7.3.1. Market Trends and Opportunities

7.3.2. Growth Prospects

7.4. Cellular Assay

7.4.1. Market Trends and Opportunities

7.4.2. Growth Prospects

7.5. Ex-vivo

7.5.1. Market Trends and Opportunities

7.5.2. Growth Prospects

8. IN-VITRO TOXICOLOGY TESTING MARKET BY APPLICATION

8.1. Introduction

8.2. Endocrine Disruption

8.2.1. Market Trends and Opportunities

8.2.2. Growth Prospects

8.3. Dermal Toxicity

8.3.1. Market Trends and Opportunities

8.3.2. Growth Prospects

8.4. Systemic Toxicology

8.4.1. Market Trends and Opportunities

8.4.2. Growth Prospects

8.5. Ocular Toxicity

8.5.1. Market Trends and Opportunities

8.5.2. Growth Prospects

8.6. Others

8.6.1. Market Trends and Opportunities

8.6.2. Growth Prospects

9. IN-VITRO TOXICOLOGY TESTING MARKET BY END-USER

9.1. Introduction

9.2. Cosmetics & Household Products

9.2.1. Market Trends and Opportunities

9.2.2. Growth Prospects

9.3. Pharmaceutical Industry

9.3.1. Market Trends and Opportunities

9.3.2. Growth Prospects

9.4. Diagnostics

9.4.1. Market Trends and Opportunities

9.4.2. Growth Prospects

9.5. Academic Institutes & Research Laboratories

9.5.1. Market Trends and Opportunities

9.5.2. Growth Prospects

9.6. Food Industry

9.6.1. Market Trends and Opportunities

9.6.2. Growth Prospects

9.7. Chemicals Industry

9.7.1. Market Trends and Opportunities

9.7.2. Growth Prospects

9.8. Others

9.8.1. Market Trends and Opportunities

9.8.2. Growth Prospects

10. IN-VITRO TOXICOLOGY TESTING MARKET BY GEOGRAPHY

10.1. Introduction

10.2. North America

10.2.1. By Product

10.2.2. By Technology

10.2.3. By Method

10.2.4. By Application

10.2.5. By End-User

10.2.6. By Country

10.2.6.1. United States

10.2.6.1.1. Market Trends and Opportunities

10.2.6.1.2. Growth Prospects

10.2.6.2. Canada

10.2.6.2.1. Market Trends and Opportunities

10.2.6.2.2. Growth Prospects

10.2.6.3. Mexico

10.2.6.3.1. Market Trends and Opportunities

10.2.6.3.2. Growth Prospects

10.3. South America

10.3.1. By Product

10.3.2. By Technology

10.3.3. By Method

10.3.4. By Application

10.3.5. By End-User

10.3.6. By Country 

10.3.6.1. Brazil

10.3.6.1.1. Market Trends and Opportunities

10.3.6.1.2. Growth Prospects

10.3.6.2. Argentina

10.3.6.2.1. Market Trends and Opportunities

10.3.6.2.2. Growth Prospects

10.3.6.3. Others

10.3.6.3.1. Market Trends and Opportunities

10.3.6.3.2. Growth Prospects

10.4. Europe

10.4.1. By Product

10.4.2. By Technology

10.4.3. By Method

10.4.4. By Application

10.4.5. By End-User

10.4.6. By Country

10.4.6.1. United Kingdom

10.4.6.1.1. Market Trends and Opportunities

10.4.6.1.2. Growth Prospects

10.4.6.2. Germany

10.4.6.2.1. Market Trends and Opportunities

10.4.6.2.2. Growth Prospects

10.4.6.3. France

10.4.6.3.1. Market Trends and Opportunities

10.4.6.3.2. Growth Prospects

10.4.6.4. Italy

10.4.6.4.1. Market Trends and Opportunities

10.4.6.4.2. Growth Prospects

10.4.6.5. Spain

10.4.6.5.1. Market Trends and Opportunities

10.4.6.5.2. Growth Prospects

10.4.6.6. Others

10.4.6.6.1. Market Trends and Opportunities

10.4.6.6.2. Growth Prospects

10.5. Middle East and Africa

10.5.1. By Product

10.5.2. By Technology

10.5.3. By Method

10.5.4. By Application

10.5.5. By End-User

10.5.6. By Country

10.5.6.1. Saudi Arabia

10.5.6.1.1. Market Trends and Opportunities

10.5.6.1.2. Growth Prospects

10.5.6.2. UAE

10.5.6.2.1. Market Trends and Opportunities

10.5.6.2.2. Growth Prospects

10.5.6.3. Others

10.5.6.3.1. Market Trends and Opportunities

10.5.6.3.2. Growth Prospects

10.6. Asia Pacific

10.6.1. By Product

10.6.2. By Technology

10.6.3. By Method

10.6.4. By Application

10.6.5. By End-User

10.6.6. By Country

10.6.6.1. Japan

10.6.6.1.1. Market Trends and Opportunities

10.6.6.1.2. Growth Prospects

10.6.6.2. China

10.6.6.2.1. Market Trends and Opportunities

10.6.6.2.2. Growth Prospects

10.6.6.3. India

10.6.6.3.1. Market Trends and Opportunities

10.6.6.3.2. Growth Prospects

10.6.6.4. South Korea

10.6.6.4.1. Market Trends and Opportunities

10.6.6.4.2. Growth Prospects

10.6.6.5. Taiwan

10.6.6.5.1. Market Trends and Opportunities

10.6.6.5.2. Growth Prospects

10.6.6.6. Thailand

10.6.6.6.1. Market Trends and Opportunities

10.6.6.6.2. Growth Prospects

10.6.6.7. Indonesia

10.6.6.7.1. Market Trends and Opportunities

10.6.6.7.2. Growth Prospects

10.6.6.8. Others

10.6.6.8.1. Market Trends and Opportunities

10.6.6.8.2. Growth Prospects

11. COMPETITIVE ENVIRONMENT AND ANALYSIS

11.1. Major Players and Strategy Analysis

11.2. Market Share Analysis

11.3. Mergers, Acquisitions, Agreements, and Collaborations

11.4. Competitive Dashboard

12. COMPANY PROFILES

12.1. Abbott Laboratories 

12.2. Agilent Technologies 

12.3. Bio-Rad Laboratories 

12.4. Covance 

12.5. Eurofins Scientific 

12.6. GE Healthcare 

12.7. Merck KGaA 

12.8. Promega Corporation 

12.9. Quest Diagnostics 

12.10. Thermo Fisher Scientific 

Abbott Laboratories 

Agilent Technologies 

Bio-Rad Laboratories 

Covance 

Eurofins Scientific 

GE Healthcare 

Merck KGaA 

Promega Corporation 

Quest Diagnostics 

Thermo Fisher Scientific